Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
ESMO Open|March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)G Villacampa, T Pascual, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockadeP Nuciforo, T Pascual, J Cortés, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
ESMO Open|October 17, 2025
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapyR Gómez-Bravo, B Walbaum, M Bergamino, et al.
ESMO Open|September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trialT Pascual, G Villacampa, M Oliveira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
ESMO Open|November 28, 2024
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational studyF Schettini, F Brasó-Maristany, T Pascual, et al.
ESMO Open|June 29, 2024
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerF Schettini, S Nucera, F Brasó-Maristany, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2023
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative studyM Oliveira, C Falato, J M Cejalvo, et al.
ESMO Open|September 25, 2025
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancerB Walbaum, O Martínez-Sáez, F Brasó-Maristany, et al.
Pageof 6